PROSTATIC NEOPLASM
Clinical trials for PROSTATIC NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new PROSTATIC NEOPLASM trials appear
Sign up with your email to follow new studies for PROSTATIC NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy may reduce need for long-term hormone drugs in prostate cancer
Disease control CompletedThis early-phase study tested a new approach for men with prostate cancer that has spread to nearby lymph nodes. The standard treatment includes radiation plus 2-3 years of hormone therapy, which can cause lasting side effects. Researchers added a targeted radioactive drug (Lu-PS…
Matched conditions: PROSTATIC NEOPLASM
Phase: PHASE1 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated May 17, 2026 05:28 UTC
-
New hope for men with recurrent prostate cancer: Ultra-Precise radiation shows promise
Disease control CompletedThis study tested a special type of radiation called stereotactic body radiation therapy (SBRT) in 17 men whose prostate cancer returned after earlier radiation. The treatment delivers high doses of radiation in just 5 sessions over 2 weeks, targeting only the tumor. The goal was…
Matched conditions: PROSTATIC NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 05:08 UTC
-
New combo shows promise in holding back prostate cancer
Disease control CompletedThis study tested a combination of two drugs, abiraterone acetate and prednisone, in 131 men with advanced prostate cancer that had not yet shown up on scans. The goal was to see if the treatment could lower a key cancer marker (PSA) and delay the time until the cancer visibly gr…
Matched conditions: PROSTATIC NEOPLASM
Phase: PHASE2 • Sponsor: Janssen Biotech, Inc. • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New radioactive cocktail shows promise for tough prostate cancers
Disease control CompletedThis study tested a radioactive drug (I-131-1095) plus a standard hormone therapy (enzalutamide) in 120 men with advanced prostate cancer that had stopped responding to another treatment (abiraterone). The goal was to see if the combination could shrink tumors and lower PSA level…
Matched conditions: PROSTATIC NEOPLASM
Phase: PHASE2 • Sponsor: Progenics Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 05, 2026 11:54 UTC
-
New EHR tool sparks heart-health talks for cancer survivors
Knowledge-focused CompletedThis study tested a computer tool that helps doctors and cancer survivors discuss heart health during follow-up visits. 645 survivors of breast, prostate, colorectal, endometrial, or lymphoma cancers took part. The tool aimed to increase conversations about heart risks and referr…
Matched conditions: PROSTATIC NEOPLASM
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated May 15, 2026 11:54 UTC